Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety roll-over study of everolimus in TSC with refractory seizures (EXIST-3 extension)
2024-516746-19-00Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, open-label, single-arm trial of everolimus in refractory epilepsy associated with tuberous sclerosis complex (TSC-RE), sponsored by Novartis. Primary endpoint: Frequency and severity of adverse events and serious adverse events. Started Nov 2024; status: completed.
02
Drugs
everolimus
03
Conditions
refractory epilepsy associated with tuberous sclerosis complex (TSC-RE)
Beyond the preview
Go deeper on 2024-516746-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516746-19-00.